1
|
Hebert JF, Funahashi Y, Emathinger JM, Nickerson MN, Groat T, Andeen NK, Gurley SB, Hutchens MP. Parental recovered acute kidney injury causes prenatal renal dysfunction and fetal growth restriction with sexually dimorphic implications for adult offspring. Front Physiol 2024; 15:1357932. [PMID: 38681142 PMCID: PMC11045984 DOI: 10.3389/fphys.2024.1357932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 03/20/2024] [Indexed: 05/01/2024] Open
Abstract
Introduction: Acute kidney injury (AKI) is rapidly increasing in global incidence and a healthcare burden. Prior maternal AKI diagnosis correlates with later pregnancy complications. As pregnancy influences developmental programming, we hypothesized that recovered parental AKI results in poor pregnancy outcomes, impaired fetal growth, and adult offspring disease. Methods: Using a well-characterized model of rhabdomyolysis-induced acute kidney injury (RIAKI), a form of AKI commonly observed in young people, we confirmed functional renal recovery by assessing glomerular filtration rate (GFR) 2 weeks following RIAKI. We bred sham and recovered RIAKI sires and dams in timed, matched matings for gestational day (GD) 16.5 and offspring (birth-12 weeks, 6 months) study. Results: Despite a normal GFR pre-pregnancy, recovered RIAKI dams at GD16.5 had impaired renal function, resulting in reduced fetoplacental ratios and offspring survival. Pregnant RIAKI dams also had albuminuria and less renal megalin in the proximal tubule brush border than shams, with renal subcapsular fibrosis and higher diastolic blood pressure. Growth-restricted offspring had a reduced GFR as older adults, with evidence of metabolic inefficiency in male offspring; this correlated with reduced renal AngII levels in female offspring from recovered RIAKI pairings. However, the blood pressures of 6-month-old offspring were unaffected by parental RIAKI. Conclusions: Our mouse model demonstrated a causal relationship among RIAKI, gestational risk, and developmental programming of the adult-onset offspring GFR and metabolic dysregulation despite parental recovery.
Collapse
Affiliation(s)
- Jessica F. Hebert
- Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, United States
| | - Yoshio Funahashi
- Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, United States
| | | | - Megan N. Nickerson
- Operative Care Division, Portland Veterans Administration Medical Center, Portland, OR, United States
| | - Tahnee Groat
- Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, United States
| | - Nicole K. Andeen
- Department of Pathology, Oregon Health and Science University, Portland, OR, United States
| | - Susan B. Gurley
- Division of Nephrology and Hypertension, Department of Medicine, Keck School Medicine of University of Southern California, Los Angeles, CA, United States
| | - Michael P. Hutchens
- Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, United States
- Operative Care Division, Portland Veterans Administration Medical Center, Portland, OR, United States
| |
Collapse
|
2
|
Hebert JF, Myatt L. Metformin Impacts Human Syncytiotrophoblast Mitochondrial Function from Pregnancies Complicated by Obesity and Gestational Diabetes Mellitus in a Sexually Dimorphic Manner. Antioxidants (Basel) 2023; 12:719. [PMID: 36978967 PMCID: PMC10044921 DOI: 10.3390/antiox12030719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 03/10/2023] [Accepted: 03/12/2023] [Indexed: 03/16/2023] Open
Abstract
Maternal obesity and gestational diabetes mellitus (GDM) are associated with placental dysfunction, small for gestational age (SGA) offspring, and programming of adult-onset disease. We examine how metformin, commonly used to treat type A2 GDM, affects placental metabolism as well as mitochondrial content and function. Syncytiotrophoblasts (STBs) were prepared from placentas of male and female fetuses collected at term cesarean section from lean (pre-pregnancy BMI < 25), obese (BMI > 30), and obese A2GDM women. Metformin treatment (0.001-10 mM) of STB caused no change in non-mitochondrial respiration but significant concentration-dependent (1 and 10 mM) decreases in basal, maximal, and ATP-linked respiration and spare capacity. Respiration linked to proton leak was significantly increased in STB of male A2GDM placentas at low metformin concentrations. Metformin concentrations ≥1 mM increased glycolysis in STB from placentas from lean women, but only improved glycolytic capacity in female STB. Whereas metformin had little effect on superoxide generation from male STB of any group, it gave a concentration-dependent decrease in superoxide generation from female STB of lean and obese women. Fewer mitochondria were observed in STB from obese women and male STB from lean women with increasing metformin concentration. Metformin affects STB mitochondrial function in a sexually dimorphic manner but at concentrations above those reported in maternal circulation (approximately 0.01 mM) in women treated with metformin for GDM.
Collapse
Affiliation(s)
| | - Leslie Myatt
- Department of Obstetrics and Gynecology, Oregon Health & Science University; Portland, OR 97239, USA
| |
Collapse
|
3
|
Ouazzani HE, Rouillon S, Venisse N, Sifer-Rivière L, Dupuis A, Cambien G, Ayraud-Thevenot S, Gourgues AS, Pierre-Eugène P, Pierre F, Rabouan S, Migeot V, Albouy-Llaty M. Impact of perinatal environmental health education intervention on exposure to endocrine disruptors during pregnancy-PREVED study: study protocol for a randomized controlled trial. Trials 2021; 22:876. [PMID: 34863252 PMCID: PMC8642981 DOI: 10.1186/s13063-021-05813-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 11/10/2021] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The suspected or actual effects on health of endocrine-disrupting chemicals (EDC) and their ubiquitous presence in everyday life justify the implementation of health promotion interventions. These interventions should ideally be applied during critical windows like pregnancy. Perinatal environmental health education interventions may help to reduce EDC exposure during pregnancy. METHODS/DESIGN PREVED (Pregnancy, PreVention, Endocrine Disruptors) is an open-label randomized controlled trial assessing the impact of environmental health education intervention on EDC exposure during pregnancy. Inclusion, consent, and randomization take place during the first trimester. The participants are randomly allocated into three groups: (i) control group (information leaflet on EDCs), (ii) intervention group in neutral location (information leaflet and workshops in a meeting room), and (iii) intervention group in contextualized location (information leaflet and workshops in a real apartment). Workshops are organized between the second and third trimesters of pregnancy. Main outcome is the percentage of participants who reported consuming manufactured/industrial food. Secondary outcomes are as follows: (i) psycho-social dimensions, (ii) EDC concentrations in urine, (iii) EDC concentration in colostrum, and (iv) percentage of participants who reported consuming paraben-free personal care products. DISCUSSION PREVED is a ground-breaking intervention research project dedicated to perinatal environmental health education that aims to identify pollutant sources in daily life and to offer accessible and realistic alternative solutions, by promoting the sharing of know-how and experience in a positive and non-alarmist approach. TRIAL REGISTRATION ClinicalTrials.gov : NCT03233984 (current status: ongoing). Retrospectively registered on 31 July 2017 ( https://clinicaltrials.gov/ct2/show/NCT03233984 ) because when the first participant was enrolled in this non-drug intervention, ClinicalTrials.gov was centered in therapeutic trials. The World Health Organization Trial Registration Data Set is in Additional file 1.
Collapse
Affiliation(s)
- Houria El. Ouazzani
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
- BioSPharm Pole, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| | - Steeve Rouillon
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
- BioSPharm Pole, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- UMR CNRS 7285, IC2MP, Poitiers, France
| | - Nicolas Venisse
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- BioSPharm Pole, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| | - Lynda Sifer-Rivière
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Research Center of Medicine, Sciences, Health and Society (Cermes 3), EHESS, University of Paris Descartes, Villejuif, France
| | - Antoine Dupuis
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
- BioSPharm Pole, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| | - Guillaume Cambien
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
| | - Sarah Ayraud-Thevenot
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
| | - Anne-Sophie Gourgues
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| | - Pascale Pierre-Eugène
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| | - Fabrice Pierre
- BioSPharm Pole, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Department of Obstetrics and Gynecology and Reproductive Medicine, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| | - Sylvie Rabouan
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
| | - DisProSE Group
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
- BioSPharm Pole, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- UMR CNRS 7285, IC2MP, Poitiers, France
- Research Center of Medicine, Sciences, Health and Society (Cermes 3), EHESS, University of Paris Descartes, Villejuif, France
- Department of Obstetrics and Gynecology and Reproductive Medicine, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| | - Virginie Migeot
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
- BioSPharm Pole, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| | - Marion Albouy-Llaty
- Health-Endocrine Disruptors-EXposome (HEDEX), INSERM-CIC1402, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
- Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
- BioSPharm Pole, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
| |
Collapse
|